Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.368 SEK | -0.15% | -2.98% | -22.80% |
Feb. 21 | Transcript : Immunovia AB, 2023 Earnings Call, Feb 21, 2024 | |
Feb. 21 | Immunovia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Sales 2021 | 844K 78.92K | Sales 2022 | 1.14M 107K | Capitalization | 595M 55.65M |
---|---|---|---|---|---|
Net income 2021 | -156M -14.59M | Net income 2022 | -168M -15.71M | EV / Sales 2021 | 1,710 x |
Net cash position 2021 | 254M 23.76M | Net cash position 2022 | 68.47M 6.4M | EV / Sales 2022 | 460 x |
P/E ratio 2021 |
-10.9
x | P/E ratio 2022 |
-3.54
x | Employees | 11 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 73.3% |
Latest transcript on Immunovia AB
1 day | -0.15% | ||
1 week | -2.98% | ||
Current month | -1.87% | ||
1 month | -8.43% | ||
3 months | -27.70% | ||
6 months | +78.59% | ||
Current year | -22.80% |
Managers | Title | Age | Since |
---|---|---|---|
Jeff Borcherding
CEO | Chief Executive Officer | - | - |
Director of Finance/CFO | 62 | 22-03-31 | |
Karl Stone
COO | Chief Operating Officer | 61 | 23-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 70 | 16-12-08 | |
Peter Andersen
CHM | Chairman | 67 | 19-12-31 |
Michael Löfman
BRD | Director/Board Member | - | 23-05-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1.368 | -0.15% | 87,403 |
24-03-27 | 1.37 | +3.63% | 246,447 |
24-03-26 | 1.322 | -2.07% | 270,261 |
24-03-25 | 1.35 | +1.50% | 418,681 |
24-03-22 | 1.33 | -12.38% | 938,951 |
Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:59 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-22.80% | 5.84M | |
-34.95% | 3.23B | |
+12.43% | 1.79B | |
-0.43% | 1.67B | |
+36.05% | 1.38B | |
-3.90% | 1.11B | |
-19.15% | 915M | |
-6.11% | 738M | |
-11.71% | 716M | |
+12.74% | 537M |